MTA-1的表达与膀胱移行细胞癌的发生及复发的关系研究

目的:探讨转移相关基因1的表达与膀胱移行细胞癌的发生及复发的关系。方法:收集临床膀胱移行细胞癌患者120例,其中初发病例62例,复发病例58例,采用RT-PCR检测MTA-1 mRNA表达的变化,Western blot检测MTA-1蛋白表达的变化。结果:与对照组比较,初发组病例和复发组病例膀胱癌组织的MTA-1 mRNA和蛋白质的表达水平均明显上调,且复发组上调更为显著。结论:转移相关基因1的表达与膀胱癌的发生呈正相关,且转移相关基因1表达的上调可能导致膀胱移行细胞癌的复发。     

膀胱移行细胞癌中EphA2的表达和肿瘤MVD计数的关系

目的:探讨膀胱移行细胞癌中EphA2的生物学意义以及EphA2与微血管密度(MVD)的关系。方法:应用免疫组织化学技术检测85例膀胱移行细胞癌及10例正常膀胱粘膜中EphA2的表达,采用CD31染色标记微血管,行肿瘤微血管密度计数。结果:膀胱移行细胞癌和正常膀胱粘膜EphA2表达阳性率分别为89.4%(76/85)、40%(4/10),两组间差异有统计学意义(P<0.01);EphA2表达程度与膀胱癌的病理分级、临床分期和淋巴结转移均有相关性(P<0.05);膀胱移行细胞癌EphA2阴性组与EphA2阳性纽间肿瘤微血管密度(MVD)计数差异有统计学意义(P<0.05),EphA2不同阳性程度组之间MVD计数差异没有统计学意义(P>0.05)。结论:EphA2可作为判定膀胱癌恶性程度的参考指标,与肿瘤微血管生成相关,有望成为膀胱癌治疗的新靶向。     

β—连接素在膀胱移行细胞癌中表达的意义

目的 探讨β－连接素（β－ctenin）蛋白的表达及其与膀胱移行细胞癌组织学特征和侵袭的关系。方法 采用免疫组化SP法检测46例膀胱移行细胞癌组织中的β－ctenin的表达。结果 正常膀胱粘膜上皮细胞全部表达β－ctenin,膀胱移行细胞癌中β－ctenin的表达率分别是“＋＋＋”为52．1％（24／46）,“＋＋”为32．6％（15／46）,“＋”O 15．2％（7／46）。侵袭型的膀胱移行细胞癌中β－ctenin表达率是“＋＋＋”为11．1％（1／9）,显著低于乳头状型者（P＜0．01）。结论 β－ctenin的表达与膀胱移行细胞组织学特征及侵袭有相关性,可作为判断肿瘤恶笥肿瘤、侵袭、预后的价值指标。     

激光捕获显微切割技术在膀胱移行细胞癌相关基因研究中的应用

背景与目的:激光捕获显微切割技术 (LCM)是获取均一目的细胞的有效方法。利用LCM技术从膀胱粘膜中分离膀胱移行上皮细胞从肿瘤间质细胞中分离膀胱癌细胞,进行RNA提取、纯化、浓缩以备进一步研究。方法:采用LCM技术分别从正常膀胱粘膜及膀胱癌组织冰冻切片中获取膀胱移行上皮细胞及膀胱癌细胞,提取RNA,并对微量RNA进行纯化、浓缩。然后用RT PCR验证TotalRNA中β actin基因表达水平。结果:对照实验Ⅰ证实经LCM后RNA完整性较好;经对照实验Ⅱ初步确定设定条件下LCMshooting次数与可获得RNA量间对应关系。从膀胱粘膜中捕获膀胱移行上皮细胞 2 5万shootings;从膀胱癌组织中获取癌细胞 2 0万shootings。经RT PCR验证β actin基因表达表达完整。结论:使用LCM技术能成功地获取较为均一的研究目的细胞,RNA完整性较好,能用于进一步研究中。     

膀胱移行细胞和移行细胞癌细胞内β-葡萄糖醛酸酶免疫电镜比较研究

β－葡萄糖醛酸酶（β－Ｇｌｕｃｕｒｏｎｉｄａｓｅ,简称β－Ｇ）在正常人体组织匀浆和体液中含量很低,本实验采用胶体金标记,免疫电镜技术,进行了人体正常移行细胞与移行细胞癌细胞内β－Ｇ定位研究,实验结果表明,β－Ｇ存在于移行细胞和移行细胞癌细胞中的内质网、溶酶体内,同时观察到癌细胞中标记β－Ｇ的金颗粒数量多于正常移行细胞中金颗粒的数量,本实验结果可能对于移行细胞癌的早期发现、早期诊断提供了新的依据。     

VEGF-D的表达与膀胱移行细胞癌LVD及淋巴结转移有关

目的观察血管内皮生长因子D(vascular endothelial growth factor D,VEGF-D)在人膀胱移行细胞癌组织内的表达,探讨VEGF-D在膀胱移行细胞癌组织淋巴管密度(lymphatic vessel density,LVD)及淋巴结转移之间的关系。方法取人膀胱移行细胞癌组织蜡块30例,免疫组化法观察VEGF-D在膀胱移行细胞癌组织内的表达情况。以淋巴管内皮特异性标记物D2-40标记淋巴管,计数癌组织内淋巴管密度。结果VEGF-D蛋白主要表达于癌细胞胞浆内,VEGF-D在淋巴结转移组膀胱移行细胞癌组织内的表达水平明显高于无淋巴结转移组(P0.05);淋巴结转移组膀胱移行细胞癌组织内的淋巴管密度明显高于无淋巴结转移组(P0.05)。VEGF-D表达与膀胱移行细胞癌淋巴管密度及淋巴结转移之间具有显著的相关性。结论VEGF-D表达在膀胱移行细胞癌组织内淋巴管生成及淋巴结转移中起重要作用。     

一氧化氮合酶（NOS）在膀胱移行细胞癌中的表达及其意义

目的检测膀胱移行细胞癌中一氧化氮合酶（nitric oxide synthase,NOS）的表达,并分析其表达与肿瘤病理特性的关系.方法采用免疫组织化学技术检测35例膀胱移行细胞癌标本、12例癌旁粘膜标本及8例正常膀胱粘膜标本中一氧化氮合酶三种亚型的表达情况.结果 35例肿瘤标本中nNOS、iNOS、eNOS阳性表达率分别为74.3%、85.7%、42.9%,膀胱移行细胞癌中iNOS表达较正常膀胱粘膜增高.但移行细胞癌、癌旁粘膜、正常粘膜三组间nNOS及eNOS表达无差别.nNOS、iNOS、eNOS表达与膀胱移行细胞癌分期分级可能无相关性.结论 iNOS在膀胱移行细胞癌中表达增高,可能参与膀胱移行细胞癌的发生发展.     

后腹腔镜治疗上尿路移行细胞癌

目的：比较后腹腔镜肾输尿管全切及膀胱袖状切除术与开放手术治疗上尿路移行细胞癌的临床疗效。方法：回顾分析我院2003年3月至2008年10月行后腹腔镜肾输尿管全切及膀胱袖状切除术治疗上尿路移行细胞癌47例,其中后腹腔镜手术26例（A组）,传统的开放手术21例（B组）。对两组的临床疗效及随访结果等进行对比研究。结果：两组在发病年龄、性别、肿瘤大小、手术时间比较差异无显著性意义;A组术中出血量（98.2±28.5）ml、术后（33.6±12.4）h肠功能恢复、（43.5±12.5）h下床活动、应用止痛药（1.5±0.5）d、静脉应用抗生素（3.5±1.1）d、术后住院天数（6.5±1.5）d、（20.0±8.5）d恢复正常工作,明显优于B组,差异有统计学意义（P＆lt;0.05）;A组并发症少于B组。两组平均随访（36.6±16.0）、（38.0±16.7）月,5年无复发生存率和总生存率比较无显著性差异（P＆gt;0.05）。结论：后腹腔镜肾输尿管切除及膀胱袖状切除术与开放手术相比,疗效相当,创伤小、痛苦少、术后恢复快、并发症少,可作为上尿路移行细胞癌的首选治疗方法。     

β-catenin和磷酸化的β-catenin在上尿路移行细胞癌中的表达及临床意义

目的探讨β- catenin在上尿路移行细胞癌中表达的临床意义.方法免疫组化法检测β-catenin和磷酸化β-catenin在38例上尿路移行细胞癌中的表达情况,并分析其与预后的关系;Western blot法检测β-catenin在26例上尿路移行细胞癌中的表达情况.结果磷酸化的β-catenin在所有标本中均为阴性表达.β-catenin随着病理分级的增高正常表达率下降(P<0.05),随着临床分期的增高,正常表达率下降(P<0.05);β-catenin异常表达方式为下调表达,没有在细胞内的分布异常;β-catenin异常表达组预后不良.结论上尿路移行细胞癌中存在β-catenin的异常表达,异常表达与预后不良有关,可作为判断预后的指标.     

Polι与移行细胞癌发生关系的实验研究

目的:检测DNA聚合酶■(Pol■)在膀胱肿瘤细胞株及移行细胞癌组织中的表达,探讨Pol■在移行细胞癌组织中表达的意义。方法:培养膀胱肿瘤细胞株BIU87细胞、T24细胞株,利用RT-PCR方法检测Pol■在膀胱肿瘤细胞株中的表达;收集人膀胱粘膜正常组织、临床膀胱肿瘤和肾盂癌的移行细胞癌组织标本,利用RT-PCR方法检测组织标本中Pol■的表达。结果:Pol■在膀胱肿瘤细胞株中丰富表达,显著高于膀胱正常粘膜组织(P<0.01);Pol■在膀胱肿瘤及肾盂癌组织的表达显著高于膀胱正常粘膜组织的表达(P<0.01),且与移行细胞癌的分级相关。结论:Pol■在移行细胞癌组织中的高表达可能与膀胱肿瘤的发生、发展相关,为进一步研究Pol■在膀胱肿瘤中表达的意义打下基础。     

A transitional cell carcinoma cell line

Summary A transitional cell carcinoma cell line, COLO 232, was derived from a primary urinary bladder tumor in a Caucasian male. In culture, COLO 232 retained distinct uroepithelial phenotypic traits and produced both carcinoembryonic antigen and adrenocorticotropic hormone. COLO 232 had a chromosome mode of 58 and retained the X and Y chromosomes. Ten marker chromosomes were identified. COLO 232 will be of value for biochemical and immunological studies. Presented in part at the 28th Annual Meeting of the Tissue Culture Association, June 7, 1977. This work was supported by Grant No. CA 15018 awarded by the National Cancer Institute, DHEW, and the Mary B. and L. H. Marshall Fund.     

Cytomorphological lesions induced by chemotherapeutic agents in transitional cell carcinoma in vitro

Summary Transitional cell carcinoma from 20 patients and two human cell lines were maintained in short-term tissue culture. Each was studied ultrastructurally before and after incubaton with cisplatinum, adriamycin, or mitomycin C. Sequential ultrastructural changes were noted and were found to be specific for each agent tested. Ultrastructural changes in the nucleoli were produced by exposure to cisplatinum or mitomycin C; alterations in the heterochromatin of the nuclei were characteristic of treatment with adriamycin. The changes in the nucleoli seen with cisplatinum have not been described previously and support an alkylating property as a mechanism of action. Intravesical chemotherapeutic agents are now commonly used in clinical treatments. The morphological changes produced by these agents are specific and may be seen in the clinical setting. This research was supported by the Veteran's Administration Merit Review grant.     

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma

In the present study we analyzed immunohistochemical expression of MAGE-A 3/4 and NY-ESO-1 in 55 samples of esophageal squamous cell carcinomas (ESCC) and their respective lymph node metastases. To our knowledge this is the first study to assess and compare the expression of these antigens in ESCC lymph node metastases. Fifty (90.9%) primary ESCC were positive for MAGE-A 3/4 and 53 (96.6%) were positive for NY-ESO-1. MAGE-A 3/4 was expressed in all lymph node metastases and the intensity of expression was high in a majority of cases. NY-ESO-1 was negative in 2 (7.1%) lymph nodes metastases, while the reaction was predominantly moderate in the positive group. In primary tumors MAGE-A 3/4 showed a significantly higher intensity of expression compared to NY-ESO-1 (P=0.047), while in lymph node metastases the intensity of expression was not significantly different (P=0.387). Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression. Intensity of MAGE-A 3/4 (P=0.461) and NY-ESO-1 (P=0.414) expression in primary tumors was not significantly different compared to the expression in their respective lymph nodes metastases. Expression of MAGE-A 3/4 in primary tumors showed significant positive correlation with primary tumor expression of NY-ESO-1 (P=0.021) but no significant correlation with the expression of MAGE-A 3/4 in lymph node metastases (P=0.056). Expression of NY-ESO-1 in primary tumors showed significant positive correlation with the expression of NY-ESO-1 in lymph node metastases (P=0.001) and significant negative correlation with patients’ age (P<0.001). Expression of MAGE-A 3/4 and NY-ESO-1 in primary tumors and lymph node metastases showed no significant correlation with prognostic parameters such as tumor grade and TNM stage (P>0.05). We have shown different levels of MAGE-A 3/4 and NY-ESO-1 expression in almost all specimens of primary tumor and lymph node metastases, suggesting that ESCC may be possible target of immunotherapy and anti-tumor vaccination. High levels of expression in lymph node metastases indicate possible clinical benefit of postoperative vaccine with MAGE-A3 and NY-ESO-1 in advanced stage of disease.     

Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder

Angiogenesis is essential for tumor growth and progression and is mediated by positive and negative regulators of vessel growth. Since angiogenic mediators found in patient serum have been postulated to reflect the angiogenic potential of a malignant tumor, we investigated the angiogenic activity in the serum of patients with transitional cell carcinoma (TCC). The data were correlated to tumor characteristics and the clinical course of the patients. Eighty-one patients with transitional cell carcinoma and 53 control persons were included in the study. Preoperative serum samples were collected and both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were quantified by ELISA. Additionally, the serum evoked proliferative activity on human umbilical vein endothelial cells (HUVEC) was evaluated. Data were compared to the clinical course of the patients. Serum of tumor patients significantly enhanced the proliferative capacity of HUVEC, compared to cells grown in standard culture medium (p = 0.0032), but not when compared to serum from control persons. Serum from patients with superficial TCC and well differentiated tumors induced a significantly higher angiogenic response (ANG(hi)) than serum from patients with poorly differentiated and invasive carcinomas (ANG(lo); p = 0.037). VEGF level of ANG(hi) serum was 384.22 +/- 247.76 pg/ml (n = 37) which significantly differed from mean VEGF level detected in ANG(lo) serum (247.72 +/- 211.93 pg/ml, n = 42; p = 0.019). Similarly, mean bFGF levels were 9.58 +/- 5.91 pg/ml in ANG(hi) serum versus 5.74 +/- 3.52 pg/ml) in ANG(lo) serum (p = 0.0043). A negative correlation was established between VEGF/bFGF serum concentration and patient prognosis. The experiments demonstrate a positive correlation between VEGF and bFGF serum level and endothelial proliferation in vitro. The inverse relationship between angiogenic activity and tumor stage might disclose information about angiogenesis and tumor progression in TCC.     

Claudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder

Updated classification of urothelial cell cancer differentiates low-grade and high-grade cancers, which determines potential clinical outcome. Substantial interobserver variability necessitates new biomarkers to ensure classification. Claudins' specific expression pattern characterizes normal tissues, different tumor types, and defined grades of tumor differentiation. The aim of this study was to examine the expression pattern of claudins and proliferation marker Ki-67 in low-grade and high-grade urothelial cell cancers compared with independent control samples of non-tumorous urothelium, as well as to reveal the predictive usefulness of claudins. The expression of claudins-1, -2, -3, -4, -5, -7, and -10 and Ki-67 was studied with quantitative immunohistochemistry and real-time RT-PCR with relative quantification in 103 samples: 86 urothelial cell cancers (27 low grade, 59 high grade) and 17 non-tumorous urothelia. Results were analyzed regarding overall survival and recurrence-free period as well. High-grade tumors overall showed significantly higher claudin-4 and Ki-67 and significantly lower claudin-7 expression when compared with low-grade ones. High-grade tumors revealed significantly shorter overall survival in Kaplan-Meier analysis. Claudin-4, claudin-7, and Ki-67 might be used as potential markers to differentiate low-grade and high-grade urothelial cell cancers, thereby possibly enhancing accuracy of pathological diagnosis and adding further information to clinical outcome.     

Co-localization of GSTP1 and JNK in transitional cell carcinoma of urinary bladder

Transitional cell carcinoma (TCC) of urinary bladder belongs to glutathione S-transferase P1 (GSTP1) overexpressing tumors. Upregulated GSTP1 in TCC is related to apoptosis inhibition. This antiapoptotic effects of GSTP1 might be mediated through protein:protein interaction with c-Jun NH(2) -terminal kinase (JNK). Herein, we analyzed whether a direct link between GSTP1 and JNK exists in TCC. The presence of GSTP1/JNK complexes was analyzed by immunoprecipitation and Western blotting in 20 TCC specimens, obtained after surgery. Co-localization of GSTP1 and JNK was also investigated in the 5637 TCC cell line by immunofluorescence confocal microscopy. By means of immunoprecipitation we show for the first time the presence of GSTP1/JNK complexes in all TCC samples studied. A co-localization of GSTP1 and JNK was also demonstrated in the 5637 TCC cell line by means of confocal microscopy. Protein-protein interactions, together with co-localization between GSTP1 and JNK provide evidence that GSTP1 most probably inhibits apoptosis in TCC cells by non-covalent binding to JNK.     

SOX2 modulates alternative splicing in transitional cell carcinoma

Aberrant alternative splicing of key cellular regulators may play a pivotal role in cancer development. To investigate the potential influence of altered alternative splicing on the development of transitional cell carcinoma (TCC), splicing activity in the TCC cell lines TSGH8301 and BFTC905 was examined using the SV40-immortalized uroepithelial cell line SV-HUC-1 as a reference. Our results indicate a significant alteration in splice site selection in the TCC cell lines. By gene expression profiling and subsequent validation, we discovered that sex-determining region Y-box protein 2 (SOX2) is specifically upregulated in BFTC905. Furthermore, ectopic expression of SOX2 modulates alternative splicing of the splicing reporter in vivo. More significantly, using an in vitro pull-down assay, it was found that SOX2 exhibits RNA-binding capability. Our observations suggest that SOX2 modulates alternative splicing by functioning as a splicing factor.     

Immunohistochemical localization of cytokeratin 17 in transitional cell carcinomas of the human urinary tract

The expression of cytokeratin (CK) 17 was studied in 28 primary transitional cell carcinomas (TCCs) of the human urinary tract using CK 17-specific monoclonal antibody E3. While CK 17 was not detectable at all or only present in some areas of basal cells in normal—appearing urothelium, a certain subpopulation of cells of all G1 and G1/G2 TCCs examined (9 cases) stained positive for CK 17. These latter cells were either restricted to the basal compartment or located also in suprabasal layers exhibiting a decreasing intensity of immunoreactivity. CK 17 was seen in practically all cells in G2 and G2/G3 tumors (7 cases). In contrast, G3 TCCs and anaplastic carcinomas showed a highly variable CK 17 staining pattern ranging from completely negative to completely positive with several intermediate phenotypes. Our results indicate that CK 17 could be a useful marker for the progression of urinary tumors.